JOURNEY MEDICAL CORPORATION - COMMON STOCK

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

06 Dec 2023 07:00:51 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

07 Nov 2023 15:01:18 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

31 Oct 2023 07:30:12 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

20 Oct 2023 07:30:59 By Nasdaq GlobeNewswire

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

06 Sep 2023 07:00:04 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

08 Aug 2023 15:01:33 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

02 Aug 2023 15:01:42 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

19 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

11 Jul 2023 07:30:20 By Nasdaq GlobeNewswire

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023

03 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

13 Jun 2023 07:30:59 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

22 May 2023 15:01:31 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

19 May 2023 15:01:27 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call

11 May 2023 15:01:01 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

04 May 2023 08:00:26 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

29 Mar 2023 15:01:11 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023

22 Mar 2023 08:00:54 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

16 Mar 2023 07:30:32 By Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in the 35th Annual ROTH Conference

07 Mar 2023 07:30:31 By Nasdaq GlobeNewswire

Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

20 Jan 2023 15:01:30 By Nasdaq GlobeNewswire